In second-line treatment of BRAF V600E mutated tumors, a targeted therapy combination with the BRAF V600E inhibitor encorafenib and the EGFR antibody cetuximab has been established by the BEACON study, finding a significantly prolonged progression-free survival, compared to the control group (FOLFIRI or irinotecan with cetuximab).467 The additional EGFR antibody targets a resistance mechanism via a feedback loop, which renders monotherapy ineffective in CRC with BRAF inhibition.468. Here, BRAF is linked to colorectal carcinoma.